HIT! High Impact Clinical Trials – Why and How

9 Feb 2025 9 a.m. 10:30 a.m.
Brahmkamal Hall - Plenary Hall
DavidWheeler Chair United KingdomUniversity College London
Winston Wing ShingFung Chair Hong Kong, ChinaPrince of Wales Hospital, Hong Kong

Time Session
9 a.m.
9:18 a.m.
What Have We Learned From CONVINCE?
HIT2-1
PeterBlankestijn Oral Abstract Presenter P.J.Blankestijn@umcutrecht.nlNetherlandsUniversity Medical Center Utrecht
9:18 a.m.
9:36 a.m.
Design of the ZEUS Trial: Interleukin-6 Inhibition With Ziltivekimab for Cardiovascular Protection in Chronic Kidney Disease
HIT2-2
VladoPerkovic Oral Abstract Presenter AustraliaUniversity of New South Wales, Sydney, Australia
9:36 a.m.
9:54 a.m.
A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
HIT2-3
Jonathan Barratt Oral Abstract Presenter United KingdomUniversity of Leicester, Leicester, UK
9:54 a.m.
10:12 a.m.
Observational Cohort With Embedded Randomized Controlled Trials to Study Pregnancy-Associated Progression of Renal Disease: A Feasibility Study of Dietary Nitrate (Beetroot Juice) to Protect Kidney Function in Pregnant Women With Chronic Kidney Disease
HIT2-4
KateBramham Oral Abstract Presenter United KingdomKing's College London
10:12 a.m.
10:30 a.m.
Design of Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven Primary Glomerular Diseases: Multi-Center, Multi-Arm and Multi-Stage
HIT2-5
Selvin Sundar RajMani Oral Abstract Presenter IndiaAssociate Professor in Nephrology, Christian Medical College, Vellore, India
SuceenaAlexander Oral Abstract Presenter IndiaChristian Medical College Vellore